Page last checked
Foundayo vs Zepbound
Foundayo is a daily orforglipron tablet. Zepbound is a weekly tirzepatide injection. Both labels cover weight management in adults, but their schedules and dosage forms differ.
Source for this answer
Source: Read from the current Foundayo and Zepbound labels
Source: Read from the current Foundayo and Zepbound labels
Reviewed 2026-09-06every number here is sourced
Foundayo and Zepbound, line by line
Compare 12 details from the two labels. Side-effect figures from separate trials do not establish which medicine is safer.
| Question | Foundayo | Zepbound |
|---|---|---|
| What is in it | Orforglipron, a nonpeptide GLP-1 receptor agonist | Tirzepatide, a GIP and GLP-1 receptor agonist |
| Dosage form | Film-coated tablet | Injection in a pen or vial |
| How often | Once daily | Once weekly |
| Food timing | With or without food | With or without meals |
| Main approved useSame on both labels | Weight reduction and keeping weight off in adults | Weight reduction and keeping weight off in adults |
| Other approved use | None | Moderate to severe obstructive sleep apnea in adults with obesity |
| Starting dose | 0.8 mg once daily | 2.5 mg once weekly for 4 weeks |
| Highest dose | 17.2 mg once daily | 15 mg once weekly |
| How doses increase | At least 30 days at each step | At least 4 weeks at each step |
| Dose the label names for staying on | None; from 5.5 mg, further increases depend on response and how well people handle it | 5, 10 or 15 mg for weight management |
| If one dose is missed | Take it as soon as possible, but never double the next dose | Take it within 4 days; otherwise skip it |
| What the label reports for nausea | 26, 34 and 35 in 100 at 5.5, 9 and 17.2 mg, against 10 on placebo | 25, 29 and 28 in 100 at 5, 10 and 15 mg, against 8 on placebo |
Product comparison at a glance
- Foundayo
- Orforglipron
- Zepbound
- Tirzepatide
- Label differences
- 11 of 12 comparison rows differ
- Direct trial
- None published
Has anyone tested Foundayo against Zepbound directly?
No trial has tested Foundayo against Zepbound directly.
The two labels report separate trials against placebo. Putting their results side by side would create a comparison that neither trial made.
What can be compared directly is what the current labels state: one tablet every day against one injection every week, two different dose ladders, and overlapping but not identical approved uses.
4Comparison details
The route changes more than the calendar
Foundayo is swallowed whole and can be taken with or without food. Zepbound is injected under the skin, and its label lists pens and vials.
The milligram figures do not share a scale. A daily tablet and a weekly injection contain different drugs, so neither label supplies a milligram-for-milligram conversion.
The approved-use lists overlap but do not match
Both labels cover long-term weight reduction in adults with obesity or overweight plus a related condition.
Zepbound also carries an indication for moderate to severe obstructive sleep apnea in adults with obesity. Foundayo’s label does not.
What about “Orforglipron vs Zepbound”?
Reversing the names does not change the product details or trial results.
Read each result with its own dose, study group and limits, whichever name comes first.
The full label for each
Choose a product below to see its full dose schedule, side effects and storage rules.
Foundayo
Zepbound
- FOUNDAYO (orforglipron) tablet, film coated [Eli Lilly and Company] — DailyMed SPL version 10, published 2026-08-13, revised 07/2026retrieved 2026-09-06FDA label
- Zepbound (tirzepatide) injection — U.S. Prescribing Information published by Eli Lillyretrieved 2026-09-06FDA label